Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Following publication of the original article [1], the authors reported the following errors in the article.

Correction to: BMC Cancer

https://doi.org/10.1186/s12885-019-5687-0

Following publication of the original article [1], the authors reported the following errors in the article.

In Table 2, the layout has been updated. The corrected Table 2 is supplied below:

Table 2

Progression-free survival by HER2 expression subgroups

	Trastuzumab + taxane (Control)		T-DM1(T-DM1)			T-DM1 + pertuzumab(T-DM1+P)
	No. patients / No. patients with PFS event	Median PFS (mo)	No. patients / No. patients with PFS event	Median PFS (mo)	HR vs. trastuzumab + taxane (97.5% CI)a	No. patients / No. patients with PFS event	Median PFS (mo)	HR vs. trastuzumab + taxane (97.5% CI)a	HR vs. T-DM1 + placebo (97.5% CI)a
All patientsb
IHC 3+	333/209	14.4	340/215	14.6	0.93 (0.75–1.16)	331/195	16.7	0.83 (0.67–1.04)	0.90 (0.72–1.12)
IHC 2+	27/19	12.6	25/20	7.3	1.13 (0.55–2.32)	29/20	8.3	1.25 (0.61–2.59)	0.98 (0.48–2.02)
IHC 2+/3+ patients combinedc
Focal IHC 2+/3+ (10–29%)d	14/8	12.4	12/10	6.4	1.51 (0.52–4.40)	15/12	7.5	1.41 (0.50–3.94)	1.00 (0.38–2.65)
Heterogeneous IHC 2+/3+ (30–79%)	35/27	10.6	37/25	8.3	1.04 (0.55–1.94)	33/20	6.3	1.11 (0.57–2.17)	0.91 (0.46–1.78)
Homogeneous IHC 2+/3+ (≥80%)	311/193	14.6	316/200	14.7	0.92 (0.74–1.16)	312/183	17.8	0.82 (0.65–1.04)	0.89 (0.71–1.13)
IHC 3+ patients only
Focal IHC 3+ (10–29%)d	9/5	8.3	11/7	8.3	1.20 (0.32–4.50)	8/7	4.2	5.11 (0.99–26.40)	2.28 (0.60–8.71)
Heterogeneous IHC 3+ (30–79%)	44/29	10.5	45/34	10.0	1.15 (0.65–2.03)	29/16	17.8	0.79 (0.39–1.60)	0.65 (0.33–1.29)
Homogeneous IHC 3+ (≥80%)	280/175	14.6	284/174	15.2	0.89 (0.70–1.14)	294/172	17.7	0.82 (0.65–1.05)	0.92 (0.73–1.17)

aUnstratified hazard ratio

bFive patients with IHC 0/1+ and five patients with unknown IHC status are not included in this table

cCategories were based on IHC subgroup and then combined

dCompared with the overall population, samples with focal HER2 expression were more likely to express mutated PIK3CA and lower levels of HER2 mRNA CI confidence interval, HER2 human epidermal growth factor receptor 2, HR hazard ratio, IHC immunohistochemistry, NE not estimable, P pertuzumab, PFS progression-free survival, PIK3CA phosphoinositide 3-kinase catalytic subunit alpha, T-DM1 trastuzumab emtansine

The legend for Fig. 3 has been adapted for clearer readability. The updated legend is as follows:

Fig. 3

Kaplan–Meier curve of PFS in subgroups defined by the presence/absence of negatively impacting biomarkers.*

*Biomarkers were considered negatively prognostic of response to HER2-targeted treatment based on their association with a numerical decrease in PFS. Specifically, these included expression of mutated PIK3CA, low HER2 mRNA level (≤median), and focal HER2 distribution. Patients without negative markers were those with nonmutated PIK3CA, high HER2 mRNA levels (>median), and non-focal (i.e., heterogeneous or homogenous) distribution of HER2. Patients with negative markers were those with mutated PIK3CA, low HER2 mRNA levels (≤median), and focal HER2 distribution. HER2 human epidermal growth factor receptor 2, PIK3CA phosphoinositide 3-kinase catalytic subunit alpha, PFS progression-free survival, T-DM1 trastuzumab emtansine

The competing interests statement has been updated below.